IL163731A0 - Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid - Google Patents

Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid

Info

Publication number
IL163731A0
IL163731A0 IL16373103A IL16373103A IL163731A0 IL 163731 A0 IL163731 A0 IL 163731A0 IL 16373103 A IL16373103 A IL 16373103A IL 16373103 A IL16373103 A IL 16373103A IL 163731 A0 IL163731 A0 IL 163731A0
Authority
IL
Israel
Prior art keywords
administration
spinal fluid
cerebral spinal
acetylcholinesterase inhibitors
acetylcholinesterase
Prior art date
Application number
IL16373103A
Other languages
English (en)
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of IL163731A0 publication Critical patent/IL163731A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16373103A 2002-05-21 2003-05-19 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid IL163731A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38212202P 2002-05-21 2002-05-21
PCT/US2003/015653 WO2004002402A2 (en) 2002-05-21 2003-05-19 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid

Publications (1)

Publication Number Publication Date
IL163731A0 true IL163731A0 (en) 2005-12-18

Family

ID=30000415

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16373103A IL163731A0 (en) 2002-05-21 2003-05-19 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid

Country Status (9)

Country Link
US (1) US20030225031A1 (enExample)
EP (1) EP1505971A2 (enExample)
JP (1) JP2005532372A (enExample)
AU (1) AU2003269874A1 (enExample)
CA (1) CA2482161A1 (enExample)
IL (1) IL163731A0 (enExample)
NZ (1) NZ535192A (enExample)
WO (1) WO2004002402A2 (enExample)
ZA (1) ZA200407420B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
JP2006518701A (ja) * 2002-05-24 2006-08-17 ネオファーム、インコーポレイティッド カルジオリピン組成物、その製造方法及び使用
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20060078560A1 (en) * 2003-06-23 2006-04-13 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis
WO2005013906A2 (en) * 2003-08-08 2005-02-17 Sri International pH-RESPONSIVE FILM FOR INTRAVAGINAL DELIVERY OF A BENEFICIAL AGENT
DE10340740A1 (de) * 2003-09-04 2005-03-31 Degussa Food Ingredients Gmbh Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
WO2006013546A2 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Process for the preparation of pure galantamine
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
EP1888056A4 (en) * 2005-06-01 2008-09-03 Teva Pharma USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
JP5362360B2 (ja) * 2005-10-11 2013-12-11 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 経鼻投与用組成物
CN1961879B (zh) * 2005-11-09 2011-11-30 上海医药工业研究院 组成石杉碱甲鼻用原位凝胶喷雾剂的药物组合物、其制备方法及用途
WO2007078879A2 (en) * 2005-12-21 2007-07-12 Vaxinnate Corporation Lipopeptide compositions and methods of use thereof
JPWO2007086493A1 (ja) * 2006-01-27 2009-06-25 旭化成ファーマ株式会社 経鼻投与用薬剤
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
JP5122791B2 (ja) * 2006-09-22 2013-01-16 石川金属株式会社 はんだ付け用フラックスおよびソルダペーストとヤニ入りはんだ
US8969402B2 (en) * 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
KR101408454B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 착색을 억제하는 방법 및 도네페질의 친척 물질의 생성량을 감소시키는 방법
DE102006056783A1 (de) * 2006-12-01 2008-06-05 Lts Lohmann Therapie-Systeme Ag Zubereitung zur transdermalen Verabreichung von Galanthamin
EP2098232B1 (en) * 2006-12-01 2013-06-05 Nitto Denko Corporation Percutaneous absorption preparation
WO2008088039A1 (ja) * 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. ドネペジルを含有する安定化医薬組成物、その製造方法、及び安定化方法
WO2008148515A1 (en) * 2007-06-05 2008-12-11 Synthon B.V. Intranasal administration of asenapine and pharmaceutical compositions therefor
CN102046171B (zh) * 2008-05-30 2013-06-19 日东电工株式会社 经皮吸收制剂
US20110056863A1 (en) * 2008-05-30 2011-03-10 Junichi Sekiya Adhesive preparation containing donepezil, and package of the same
KR20120102630A (ko) 2009-11-26 2012-09-18 쿠아크 파마수티칼스 인코퍼레이티드 말단 치환체를 포함하는 에스아이 알엔에이 화합물
CA2818024C (en) 2010-12-06 2019-09-24 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
BR112013033488B8 (pt) * 2011-06-27 2022-11-22 Eisai R&D Man Co Ltd Métodos para facilitar o diagnóstico do comprometimento cognitivo devido a doença de alzheimer ou comprometimento cognitivo leve (mci)e kit
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
AU2013312240A1 (en) * 2012-09-10 2015-03-19 Ophirex Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
WO2014043291A1 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded nucleic acid compounds
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
EP3027223A1 (en) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
WO2015148480A1 (en) 2014-03-25 2015-10-01 Emicipi Llc Treatment of rett syndrome
EP2979688A1 (en) * 2014-08-01 2016-02-03 Britannia Pharmaceuticals Limited Composition containing Apomorphine and a Divalent Metal Cation
ES2822562T3 (es) * 2014-10-03 2021-05-04 Lachesis Biosciences Ltd Composiciones intranasales para el tratamiento de enfermedades y trastornos neurológicos y degenerativos
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
WO2018092765A1 (ja) * 2016-11-15 2018-05-24 学校法人同志社 経鼻投与用医薬組成物
CN107375945B (zh) * 2017-08-29 2020-10-13 沈阳药科大学 一种多奈哌齐环糊精包合物及含有此包合物的口服速溶膜剂
CN110507610A (zh) * 2019-07-24 2019-11-29 西北农林科技大学 一种含有维生素d的纳米乳药物及其制备方法
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CU24720B1 (es) 2020-11-24 2024-10-09 Centro De Neurociencias De Cuba Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
US12109202B2 (en) 2021-01-29 2024-10-08 Qaam Pharmaceuticals, Llc Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders
CN114432495B (zh) * 2021-12-09 2022-09-20 中国人民解放军空军军医大学 一种可促进内源性骨再生的生物材料及其制备方法和应用
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
CN115919767B (zh) * 2022-10-13 2023-08-11 暨南大学 卡巴拉汀鼻喷雾剂及其制备方法
CN116602918A (zh) * 2023-02-24 2023-08-18 中国药科大学 一种多奈哌齐鼻喷剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2115256A1 (en) * 1991-08-10 1993-02-18 Masaru Saita Phenylalkanoic acid derivatives, process for producing the same and process for separating optical isomers thereof
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU785007B2 (en) * 1999-11-24 2006-08-24 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
US20040028613A1 (en) * 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery

Also Published As

Publication number Publication date
ZA200407420B (en) 2006-06-28
CA2482161A1 (en) 2004-01-08
EP1505971A2 (en) 2005-02-16
JP2005532372A (ja) 2005-10-27
WO2004002402A3 (en) 2004-10-07
WO2004002402A2 (en) 2004-01-08
NZ535192A (en) 2006-05-26
US20030225031A1 (en) 2003-12-04
AU2003269874A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
IL163731A0 (en) Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
IL172621A0 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
IL166280A0 (en) Treatment of TNF? related disorders
PL1673104T5 (pl) Dostarczanie związków terapeutycznych do mózgu i do innych tkanek
EP1638605A4 (en) DISTRIBUTION OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUE
AU2003286741A8 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
PT1487828E (pt) Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias
GB0305150D0 (en) Use of therapeutic compounds
AU2003247140A1 (en) Delivering compounds to the brain by modifying properties of the bbb and cerebral circulation
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
AU2003250317A8 (en) Device for administration of fluids
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
AU2002350832A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
PL1740204T3 (pl) Lecznicze zastosowanie alfa-mannozydazy
EP1651956A4 (en) MELKS AS MODIFIERS OF THE ACTION ACTION MECHANISM AND METHODS OF USE
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
HK1069116A (en) Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
GB2410744B (en) Kinase inhibitors for the treatment of disease
GB0201025D0 (en) The treatment of degenerative diseases
AU4838301A (en) Treatment of disorders relating to the serotonergic system
AU2003237524A1 (en) Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
IL175674A0 (en) Method to improve the efficacy of therapeutic radiolabeled drugs
HUP0402664A3 (en) 2-indanylamino derivatives for the therapy of chronic pain
GB0312844D0 (en) Use of compounds in medicine
AU2003228532A8 (en) Methods of use of the enzymes of mycothiol synthesis